- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
SPEX Market Currents
more »
-
September 9, 2011 Microcap biopharmaceutical company Spherix (SPEX +105%) soars after saying that its drug candidate, SPX-106, achieved statistically significant reductions in VLDL and LDL cholesterol when administered to genetically engineered mice prone to dyslipidemia.
Comment![Healthcare, On the Move]
SPEX in Focus
more »
SPEX Related Articles
more »
SPEX News
more »
Currently, there are no news on SPEX.
SPEX Press Releases and Filings
more »
-
GlobeNewswire (May 15, 2012)
-
PR Newswire (Apr 18, 2012)
-
PR Newswire (Apr 10, 2012)
-
PR Newswire (Mar 28, 2012)
-
PR Newswire (Jan 11, 2012)
SPEX Latest Transcript
more »
Currently, there are no transcripts for SPEX.
SPEX Cramer
more »
Currently, there are no Cramer articles on SPEX.
SPEX Instablog posts
more »
SPEX vs. ETF Alternatives
Company Description
Currently, there's no company description for SPEX.
